Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ($1349) - buy or sell? Stock discussion, ideas, forum

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Fudan-Zhangjiang Bio-pharmaceutical Company Limited researches, develops, and sells self-developed bio-pharmaceutical know-how.

Industry: Biotechnology

Ticker	Exchange	ISIN	Name
$1349	HKEx Main Board	CNE1000000W4	Code: 1349

Recent news

TAI Ping Carpet International Ltd revenue jumped on 34.8% while EBITDA Margin decreased on 2.8 pp from 9.9% to 7.1%

Vision Fame International Holding Ltd revenue growth accelerated from 2.3% in FY2019 to 405% in FY2020

Kantone Holdings Ltd reports 13.0% EBITDA growth in 2020 and 0.61 pp EBITDA Margin growth from 5.7% to 6.3%

Heng Tai Consumables Group Ltd revenue dropped on 35.5% and EBITDA Margin dropped on 19.0 pp from -27.6% to -46.6%

Yat Sing Holdings Ltd revenue decreased on 8.4% and EBITDA Margin decreased on 2.2 pp from -1.7% to -3.9%

Art Textile Technology International Co Ltd Net Debt / EBITDA surged on 82.8x from 3.9x to 86.8x in 2020 while Revenue dropped on 24.7%

China Zenith Chemical Group Ltd revenue dropped on 39.8% while EBITDA Margin surged on 93.4 pp from -149% to -55.4%

Odella Leather Holdings Ltd revenue returned to growth in FY2020: increased 60.4% vs. 48.6% decline a year earliner

New World Development Co Ltd Net Income dropped on 85.3% and Revenue dropped on 23.1%

NWS Holdings Ltd reports 80.3% Net Income decline in 2020 and 3.4% Revenue decline

Twit about 1349 stock

Share your investment idea or question on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd stock:

Latest twits on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349)

No twits yet. Be the first to post!

Have a question about 1349? Ask and other investors will be eager to help you.

Have an idea about 1349? Share it with other investors.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd news

16/03/2017 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd reports 9.1% EBITDA growth in 2016 and almost no change in EBITDA Margin of 29.8%

25/03/2016 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd demonstrated healthy growth in recent years

18/03/2016 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd reports 23.1% revenue growth in 2015 and 2.1 pp EBITDA Margin decline from 31.5% to 29.3%

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd stock price chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd financials

mln. CNY	FY2010	FY2011	FY2012

Revenue	92.390	133.9	232.5
EBITDA	-6.273	47.481	77.582
Net income	3.681	30.826	53.159
CAPEX	9.406	32.988	114.6
Debt	72.980	78.310	126.5
Cash	90.305	110.1	158.3

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd news

About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Fudan-Zhangjiang Bio-pharmaceutical Company Limited researches, develops, and sells self-developed bio-pharmaceutical know-how. The Company also carries out contracted research for customers, manufactures and sells diagnostic reagent, and provides related ancillary services in China.